Article Sidebar

PDF
Date Published: 24/02/2023
Abstract Views: 431
Views PDF: 327
DOI: https://doi.org/10.51298/vmj.v523i1.4424
Issue
Vol. 523 No. 1 (2023)
Section
Các bài báo
How to Cite
Thái, T. P. T., Trương, T. H., & Trần , H. T. . (2023). STUDY OF LIPOPROTEIN (A) CONCENTRATIONS IN PATIENTS WITH ATHEROSCLEROTIC CORONARY ARTERY DISEASE. Vietnam Medical Journal, 523(1). https://doi.org/10.51298/vmj.v523i1.4424

STUDY OF LIPOPROTEIN (A) CONCENTRATIONS IN PATIENTS WITH ATHEROSCLEROTIC CORONARY ARTERY DISEASE

Thị Phương Thảo Thái1,, Thanh Hương Trương2, Huy Thịnh Trần 2
1 Huu Nghi hospital
2 Hanoi medical university

Main Article Content

Abstract

A cross-sectional descriptive study of 450 subjects with a diagnosis of chronic coronary artery syndrome at Huu Nghi hospital, divided into two groups: group I (150 subjects with coronary artery stenosis < 50%), group II (300 subjects with coronary artery stenosis ≥ 50%). Lipoprotein (a) concentration was test at the department of Biochemintry, Bach Mai hospital. The results show that lipoprotein (a) concentration is a non-standard distribution, in group II, lipoprotein (a) concentration (33,22 ± 50 nmol/l) was statistically significantly higher than in group I (22,99 ± 32,25 nmol/l). Lipoprotein (a) is a risk factor for atherosclerotic coronary artery disease with OR: 1,008; 95%CI: 1,003-1,014.

Article Details

Keywords

Lipoprotein (a), chronic coronary artery syndrome

References

1. Phạm Mạnh Hùng. Lâm sàng Tim mạch học. Nhà xuất bản Y học; 2019
2. Baigent C, Koskinas KC, Casula M, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: 78
3. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology. 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010
4. Jennifer L. Kelsey et al. Methods in Observational Epidemiology. 2nd edition. Oxford University Press; 1996
5. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147
6. Li C, Chen Q, Zhang M, et al. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL.
7. BMC Cardiovasc Disord. 2021;21:41. doi:10.1186/s12872-021-01861-6
8. Dai W, Long J, Cheng Y, Chen Y, Zhao S. Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. Sci Rep. 2018;8:7726. doi:10.1038/s41598-018.25835-5
9. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020; 41(24): 2275-2284. doi:10.1093/eurheartj/ehz310